Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation

Ishikawa, Masashi; Iwasaki, Masae; Sakamoto, Atsuhiro; Ma, Daqing

doi:10.1186/s12871-021-01294-w

Cited by 18 publications

(13 citation statements)

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study of lung cancer also demonstrated the direct effect of opiates on cancer progression ( 23 ). The underlying molecular mechanisms remain elusive but it may be involved with the target receptors of opioids and downstream signaling pathways, induced by microRNAs’ modification ( 24 ). MOR overexpression promoted hepatocellular carcinoma cell proliferation and metastasis ability through EMT signaling pathway ( 11 ).…”

Section: Discussionmentioning

confidence: 99%

Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundOpioids are widely used for patients with solid tumors during surgery and for cancer pain relief. We conducted a pan-cancer genomic analysis to investigate the prognostic features of Mu opioid receptor (MOR) mRNA expression across 18 primary solid cancers.MethodsAll the data of cancer with MOR mRNA were retrieved from cBioPortal for Cancer Genomics. Logistic regression was used to determine the associations between MOR mRNA expression and clinicopathological features. Log-rank test and Cox regression was used for survival analysis. Subgroup analysis and propensity score matching were also carried out.Results7,274 patients, including 1,112 patients with positive MOR mRNA expression, were included for data analyses. Positive MOR mRNA expression was associated with more advanced stage of T (adjusted Odds ratio [OR], 1.176; 95% confidence interval [CI], 1.022-1.354; P=0.024), M (adjusted OR, 1.548; 95% CI, 1.095-2.189; P=0.013) except N (adjusted OR, 1.145; 95% CI, 0.975-1.346; P=0.101), and worse prognosis for overall survival (Hazard ratio [HR] 1.347, 95% CI 1.200-1.512, P<0.001), progression-free survival (HR 1.359, 95% CI 1.220-1.513, P<0.001), disease-free survival (HR 1.269, 95% CI 1.016-1.585, P<0.001) and disease-specific survival (HR 1.474, 95% CI 1.284-1.693, P<0.001). Patients with positive MOR mRNA expression tended to be classified as tumor microenvironment immune types II, representing low PD-L1 and low CD8A expression.ConclusionMOR mRNA overexpression is associated with poor prognosis and poor response to PD-L1 therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…-Inhibition of HIF-1α protein synthesis induced by hypoxia [80]; -Inhibition of the mRNA expression of MMP-2 and MMP-9 and p38 MAPK signaling (signaling pathway regulating proliferation, cell motility, and survival) [81]; -Inhibition of the NF-κB pathway [82]; -Downregulation of S100A4 in endothelial cells and suppression of VEGF expression from cancer cells with consequent anti-angiogenic effects [83,84]; -Upregulating miRNA expression (tumor suppressors and by inhibiting the expression of miRNAs that works as oncogenes) [85]; -Inhibiting histone acetylation [86].…”

Section: Anesthetic Agents Volatile and Intravenous Anestheticsmentioning

confidence: 99%

Anesthesia and cancer recurrence: an overview

Brogi

Forfori

2022

J Anesth Analg Crit Care

View full text Add to dashboard Cite

Several perioperative factors are responsible for the dysregulation or suppression of the immune system with a possible impact on cancer cell growth and the development of new metastasis. These factors have the potential to directly suppress the immune system and activate hypothalamic-pituitary-adrenal axis and the sympathetic nervous system with a consequent further immunosuppressive effect.Anesthetics and analgesics used during the perioperative period may modulate the innate and adaptive immune system, inflammatory system, and angiogenesis, with a possible impact on cancer recurrence and long-term outcome. Even if the current data are controversial and contrasting, it is crucial to increase awareness about this topic among healthcare professionals for a future better and conscious choice of anesthetic techniques.In this article, we aimed to provide an overview regarding the relationship between anesthesia and cancer recurrence. We reviewed the effects of surgery, perioperative factors, and anesthetic agents on tumor cell survival and tumor recurrence.

show abstract

“…There are more than 1500 miRNA molecules in human body, and miRNAs play critical roles in various cell biology ( 73 , 74 ). Variations of miRNA expression may affect cancer cell activity and lead to tumor recurrence and metastasis ( 75 , 76 ). Studies have reported that sevoflurane suppresses breast cancer cell proliferation by upregulating miR-203 ( 77 ).…”

Section: Effects Of Sevoflurane and Propofol On Microenvironments Of Breast Cancer Cellsmentioning

confidence: 99%

Effects of Propofol Versus Sevoflurane on Postoperative Breast Cancer Prognosis: A Narrative Review

et al. 2022

View full text Add to dashboard Cite

Perioperative interventions produce substantial biologic perturbations which are associated with the risk of recurrence after cancer surgery. The changes of tumor microenvironment caused by anesthetic drugs received increasing attention. Till now, it’s still unclear whether or not anesthetic drugs may exert positive or negative impact on cancer outcomes after surgery. Breast cancer is the most common tumor and the leading cause of cancer deaths in women. Propofol and sevoflurane are respectively the most commonly used intravenous and inhaled anesthetics. Debates regarding which of the two most commonly used anesthetics may relatively contribute to the recurrence and metastasis vulnerability of breast cancer postoperatively remain. This review aimed to provide a comprehensive view about the effect of propofol versus sevoflurane on the prognosis of breast cancer obtained from pre-clinical studies and clinical studies. Laboratory and animal studies have demonstrated that sevoflurane may enhance the recurrence and metastasis of breast cancer, while propofol is more likely to reduce the activity of breast cancer cells by attenuating the suppression of the immune system, promoting tumor cells apoptosis, and through other direct anti-tumor effects. However, retrospective clinical studies have shown contradictory results about the effects of propofol and sevoflurane on long-term survival in breast cancer patients. Furthermore, recent prospective studies did not identify significant differences between propofol and sevoflurane in breast cancer metastasis and recurrence. Therefore, more preclinical studies and randomized controlled studies are needed to guide the choice of anesthetics for breast cancer patients.

show abstract

Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation

Cited by 18 publications

References 179 publications

Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis

Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis

Anesthesia and cancer recurrence: an overview

Effects of Propofol Versus Sevoflurane on Postoperative Breast Cancer Prognosis: A Narrative Review

Contact Info

Product

Resources

About